| scholarly article | Q13442814 |
| P50 | author | John Svaren | Q37611432 |
| P2093 | author name string | James Inglese | |
| Ryan MacArthur | |||
| Sung-Wook Jang | |||
| Camila Lopez-Anido | |||
| P2860 | cites work | Comparative analysis of Schwann cell lines as model systems for myelin gene transcription studies. | Q40706590 |
| Fusions to beta-lactamase as a reporter for gene expression in live mammalian cells | Q40848158 | ||
| N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma | Q41289818 | ||
| The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity | Q41566049 | ||
| PMP22 accumulation in aggresomes: implications for CMT1A pathology | Q41697207 | ||
| P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy | Q42455824 | ||
| Post-transcriptional regulation of the peripheral myelin protein gene PMP22/gas3. | Q42819718 | ||
| Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib‐induced peripheral neuropathy | Q42911212 | ||
| Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). | Q44649327 | ||
| Quantum yields and quantitative spectra of firefly bioluminescence with various bivalent metal ions. | Q50523135 | ||
| An 8.5-kb segment of the PMP22 promoter responds to loss of axon signals during Wallerian degeneration, but does not respond to specific axonal signals during nerve regeneration. | Q52057126 | ||
| Identification of the regulatory region of the peripheral myelin protein 22 (PMP22) gene that directs temporal and spatial expression in development and regeneration of peripheral nerves. | Q52118842 | ||
| DNA deletion associated with hereditary neuropathy with liability to pressure palsies | Q55670941 | ||
| Charcot-Marie-Tooth disease | Q61051025 | ||
| Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters | Q72724419 | ||
| Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression | Q81570572 | ||
| The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies | Q82615309 | ||
| Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus | Q24600383 | ||
| Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C | Q27658802 | ||
| Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124 | Q27660081 | ||
| A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays | Q28145712 | ||
| Gene duplication: a drive for phenotypic diversity and cause of human disease | Q28294965 | ||
| Retinoic acid regulates myelin formation in the peripheral nervous system | Q28577211 | ||
| Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination | Q30856297 | ||
| Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries | Q33251617 | ||
| A specific mechanism for nonspecific activation in reporter-gene assays | Q33347807 | ||
| Apparent activity in high-throughput screening: origins of compound-dependent assay interference | Q33563613 | ||
| Myelin synthesis in the peripheral nervous system. | Q33869411 | ||
| SOX10 directly modulates ERBB3 transcription via an intronic neural crest enhancer | Q33932242 | ||
| Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease | Q33976802 | ||
| Krox-20 controls myelination in the peripheral nervous system | Q34324119 | ||
| Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. | Q34713834 | ||
| The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics | Q34992596 | ||
| Regulation of the PMP22 gene through an intronic enhancer | Q35001004 | ||
| Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial | Q35159258 | ||
| Neuropharmacological mechanisms of capsaicin and related substances | Q35333748 | ||
| Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain | Q36485148 | ||
| c-Jun is a negative regulator of myelination. | Q36660683 | ||
| High-throughput screening assays for the identification of chemical probes | Q36885398 | ||
| Peripheral myelin protein 22 is regulated post-transcriptionally by miRNA-29a | Q37268768 | ||
| Gene copy number variation and common human disease | Q37650988 | ||
| Nrg1/ErbB signaling networks in Schwann cell development and myelination | Q37787450 | ||
| Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. | Q40170570 | ||
| The transcription factor Sox10 is a key regulator of peripheral glial development. | Q40423560 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 1205-1213 | |
| P577 | publication date | 2012-05-02 | |
| P1433 | published in | ACS Chemical Biology | Q165583 |
| P1476 | title | Identification of drug modulators targeting gene-dosage disease CMT1A. | |
| P478 | volume | 7 |
| Q27012700 | A brief review of recent Charcot-Marie-Tooth research and priorities |
| Q41357926 | Caveats in the Established Understanding of CMT1A. |
| Q28650560 | Collaboration for rare disease drug discovery research |
| Q64043670 | Doing it All - How Families are Reshaping Rare Disease Research |
| Q27671683 | Firefly Luciferase in Chemical Biology: A Compendium of Inhibitors, Mechanistic Evaluation of Chemotypes, and Suggested Use As a Reporter |
| Q34576213 | Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease |
| Q57961466 | Genome-Edited Cell Lines for High-Throughput Screening |
| Q46300376 | Genomic disorders 20 years on-mechanisms for clinical manifestations |
| Q36276587 | Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene |
| Q45222726 | PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker |
| Q37715520 | PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies |
| Q28487785 | Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays |
| Q33622527 | Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy |
| Q90504875 | Regulating PMP22 expression as a dosage sensitive neuropathy gene |
| Q57961452 | Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer |
| Q37530126 | Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development |
| Q42443417 | The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A. |
| Q35756877 | Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods |
Search more.